Omega-3 polyunsaturated fatty acids and anxiety disorders

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 81, Issue 5-6, 2009, Pages 309-312

  Ross, Brian M ^a  

^a NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PLACEBO; POLYUNSATURATED FATTY ACID; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; DEPRESSION; FATTY ACID TRANSPORT; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MOOD DISORDER; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; SOCIAL PHOBIA; TRANQUILIZING ACTIVITY; VASODILATATION;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; MOOD DISORDERS;

EID: 71749121383     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2009.10.004     Document Type: Article

References (57)

1. American Psychiatric Association, Diagnostic and statistical manual of mental disorders, 4th Edition.American Psychiatric Publishing Inc., Arlinglton, 1994.
2. Kalra H., Kamath P., Trivedi K.J., and Janca A. Caregiver burden in anxiety disorders. Curr. Opin. Psychiatry 21 (2008) 70-73
3. Batelaan N., Smit F., de Graaf R., van Balkom A., Vollebergh W., and Beekman A. Economic costs of full-blown and subthreshold panic disorder. J. Affect Disord. 104 (2007) 127-136
4. Hoffman D.L., Dukes E.M., and Wittchen H.U. Human and economic burden of generalized anxiety disorder. Depress Anxiety 25 (2008) 72-90
5. Andlin-Sobocki P., and Wittchen H.U. Cost of anxiety disorders in Europe. Eur. J. Neurol. 12 Suppl 1 (2005) 39-44
6. Lépine. J.P. The epidemiology of anxiety disorders: prevalence and societal costs. J. Clin. Psychiatry 63 Suppl 14 (2002) 4-8
7. Doyle A.C., and Pollack M.H. Establishment of remission criteria for anxiety disorders. J. Clin. Psychiatry 64 Suppl 15 (2003) 40-45
8. Kessler R.C., Chiu W.T., Demler O., and Walters E.E. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch. Gen. Psychiatry 62 (2005) 617-627
9. Nardi A.E. Early diagnosis can decrease the social and economic burden of social anxiety disorder. Aust. N Z J. Psychiatry 39 (2005) 641-642
10. Hirschfeld. R. The comorbidity of major depression and anxiety disorder: recognition and management in primary care. J. Clin. Psychiatry 3 (2001) 244-254
11. Sartorius N., Ustün T.B., Lecrubier Y., and Wittchen H.U. Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br. J. Psychiatry 6 Suppl (1996) 38-43
12. Olfson M., Fireman B., Weissman M.M., Leon A.C., Sheehan D.V., Kathol R.G., Hoven C., and Farber L. Mental disorders and disability among patients in a primary care group practice. Am. J. Psychiatry 154 (1997) 1734-1740
13. Mayberg H., Liotti M., Brannan S., McGinnis S., Mahurin K., Jerabek P., Silva J.A., Tekell J.L., Martin C.C., Lancaster J.L., and Fox P.T. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am. J. Psychiatry 156 (1999) 675-682
14. Stone E.A., Lin Y., and Quartermain. D. A final common pathway for depression? Progress toward a general conceptual framework. Neurosci. Biobehav. Rev. 32 (2008) 508-524
15. Mitchell P.B., Parker G.B., Gladstone G.L., Wilhelm K., and Austin M.P. Severity of stressful life events in first and subsequent episodes of depression: the relevance of depressive subtype. J. Affect Disord. 73 (2003) 245-252
16. Höschl C., and Svestka J. Escitalopram for the treatment of major depression and anxiety disorders. Expert Rev. Neurother. 8 (2008) 537-552
17. Mayberg H.S., Brannan S.K., Tekell J.L., Silva J.A., Mahurin R.K., McGinnis S., and Jerabek P.A. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol. Psychiatry 48 (2000) 830-843
18. Peet M., and Horrobin. D.F. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry 59 (2002) 913-919
19. Nemets B., Stahl Z., and Belmaker R.H. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. J. Psychiatry 159 (2002) 477-479
20. Nemets H., Nemets B., Apter A., Bracha Z., and Belmaker. R.H. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am. J. Psychiatry 163 (2006) 1098-1100
21. Su K.P., Huang S.Y., Chiu C.C., and Shen. W.W. A preliminary double-blind, placebo-controlled trial. Omega-3 fatty acids in major depressive disorder. Eur. Neuropsychopharmacol. 13 (2003) 267-271
22. Stoll A.L., Severus W.E., Freeman M.P., Rueter S., Zboyan H.A., Diamond E., Cress K.K., and Marangell L.B. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 56 (1999) 407-412
23. Frangou S., Lewis M., and McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br. J. Psychiatry 188 (2006) 46-50
24. Freeman M.P., Hibbeln J.R., Wisner K.L., Davis J.M., Mischoulon D., Peet M., Keck Jr. P.E., Marangell L.B., Richardson A.J., Lake J., and Stoll. A.L. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J. Clin. Psychiatry 67 (2006) 1954-1967
25. Ross B.M., Senguin J., and Sieswerda. L. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?. Lipids in Health Dis. 6 (2007) 21
26. Lin P.Y., and Su. K.P. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J. Clin. Psychiatry 68 (2007) 1056-1061
27. Maes M., Christophe A., Delanghe J., Altamura C., Neels H., and Meltzer H.Y. Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res. 85 (1999) 275-291
28. Maes M., Smith R., Christophe A., Cosyns P., Desnyder R., and Meltzer H. Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20:4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J. Affect Disord. 38 (1996) 35-46
29. Tiemeier H., van Tuijl H.R., Hofman A., Kiliaan A.J., and Breteler M.M. Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam Study. Am. J. Clin. Nutr. 78 (2003) 40-46
30. Frasure-Smith N., Lesperance F., and Julien P. Major depression is associated with lower omega-3 fatty acid levels in patients with recent acute coronary syndromes. Biol. Psychiatry 55 (2004) 891-896
31. Peet M., Murphy B., Shay J., and Horrobin D. Depletion of omega-3 PUFA levels in red blood cell membranes of depressive patients. Biol. Psychiatry 43 (1998) 315-319
32. Edwards R., Peet M., Shay J., and Horrobin. D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J. Affect Disord. 48 (1998) 149-155
33. de Vriese S.R., Christophe A.B., and Maes M. Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. Life Sci. 7 73 (2003) 3181-3187
34. Ross B.M. Omega-3 fatty acid deficiency in major depressive disorder is caused by the interaction between diet and a genetically determined abnormality in phospholipid metabolism. Med. Hypotheses 68 (2007) 515-524
35. Hibbeln JR. Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. J. Affect Disord. 69 (2002) 15-29
36. Suzuki S., Akechi T., Kobayashi M., Taniguchi K., Goto K., Sasaki S., Tsugane S., Nishiwaki Y., Miyaoka H., and Uchitomi Y. Daily omega-3 fatty acid intake and depression in Japanese patients with newly diagnosed lung cancer. Br. J. Cancer 90 (2004) 787-793
37. Tanskanen A., Hibbeln J.R., Tuomilehto J., Uutela A., Haukkala A., Viinamaki H., Lehtonen J., and Vartiainen E. Fish consumption and depressive symptoms in the general population in Finland. Psychiatr. Serv. 52 (2001) 529-531
38. Iribarren C., Markovitz J.H., Jacobs Jr. D.R., Schreiner P.J., Daviglus M., and Hibbeln J.R. Dietary intake of n-3, n-6 fatty acids and fish: relationship with hostility in young adults-the CARDIA study. Eur. J. Clin. Nutr. 58 (2004) 24-31
39. Buydens-Branchey L., Branchey M., and Hibbeln J.R. Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 568-575
40. Moscovitch D.A., McCabe R.E., Antony M.M., Rocca L., and Swinson R.P. Anger experience and expression across the anxiety disorders. Depress Anxiety 25 (2008) 107-113
41. Fava M. Depression with anger attacks. J. Clin. Psychiatry 59 Suppl 18 (1998) 18-22
42. van Praag H.M. Anxiety and increased aggression as pacemakers of depression. Acta Psychiatr. Scand. Suppl. 393 (1998) 81-88
43. Green P., Hermesh H., Monselise A., Marom S., Presburger G., and Weizman A. Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder. Eur. Neuropsychopharmacol. 16 (2006) 107-113
44. Muntaner C., Eaton W.W., Miech R., and O'Campo P. Socioeconomic position and major mental disorders. Epidemiol. Rev. 26 (2004) 53-62
45. Morrow J.D., Awad J.A., Oates J.A., and Roberts II L.J. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J. Invest Dermatol. 98 (1992) 812-815
46. Katzman M., Cornacchi S., Coonerty-Femiano A., Hughes B., Vermani M., Struzik L., and Ross B.M. Methyl nicotinate-induced vasodilation in generalized social phobia. Neuropsychopharmacology 28 (2003) 1846-1851
47. Ross B.M., Ward P., and Glen I. Delayed vasodilatory response to methylnicotinate in patients with unipolar depressive disorder. J. Affect Disord. 82 (2004) 285-290
48. Song C., Li X., Leonard B.E., and Horrobin D.F. Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats. J. Lipid Res. 44 (2003) 1984-1991
49. 2 activity and corticosterone secretion. Neuropsychopharmacology 32 (2007) 736-744
50. Hamilton. M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 32 (1959) 50-55
51. Yehuda S., Rabinovitz S., and Mostofsky D.I. Mixture of essential fatty acids lowers test anxiety. Nutr. Neurosci. 8 (2005) 265-267
52. Emken E.A., Adlof R.O., and Gulley R.M. Dietary linoleic acid influences desaturation and acylation of deuterium-labeled linoleic and linolenic acids in young adult males. Biochim. Biophys. Acta 1213 (1994) 277-288
53. Hamazaki K., Itomura M., Huan M., Nishizawa H., Sawazaki S., Masatoshi T., Watanabe S., Hamazaki T., Terasawa K., and Yazawa K. Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: a randomized, placebo-controlled, double-blind trial. Nutrition 21 (2005) 705-710
54. Zeev K., Michael M., Ram K., and Hagit C. Possible deleterious effects of adjunctive omega-3 fatty acids in post-traumatic stress disorder patients. Neuropsychiatr. Dis. Treat. 1 (2005) 187-190
55. Fux M., Benjamin J., and Nemets. B. A placebo-controlled cross-over trial of adjunctive EPA in OCD. J. Psychiatr. Res. 38 (2004) 323-325
56. Buydens-Branchey L., and Branchey M. n-3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers. J. Clin. Psychopharmacol. 26 (2006) 661-665
57. Buydens-Branchey L., Branchey M., and Hibbeln J.R. Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 568-575